Article Text

THU0416 Prevalence of Comorbidities and Risk Factors in Spondyloarthritis in Latin America: A Comparative Study with General Population: Data from The Multinational Asas-Comospa Study
  1. W. Bautista-Molano1,2,
  2. R. Landewé3,
  3. A. Moltό4,
  4. R. Burgos-Vargas5,
  5. J. Maldonado-Cocco6,
  6. R. Valle-Oñate7,
  7. D. van der Heijde1
  1. 1Rheumatology Department, Leiden University Medical Center, Leiden, Netherlands
  2. 2Rheumatology Department, School of Medicine, HMC/UMNG, Bogotá, Colombia
  3. 3Rheumatology Department, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
  4. 4Rheumatology B Department, Paris Descartes University, Cochin Hospital, AP-HP, Paris, France
  5. 5Servicio de Reumatología, Hospital General de México and Universidad Nacional Autόnoma de México, Mexico City, Mexico
  6. 6Rheumatology Section, Instituto de Rehabilitaciόn Psicofísica and Argentine Rheumatologic Foundation “Dr Osvaldo Carcia Morteo”, Buenos Aires, Argentina
  7. 7Rheumatology Department, School of Medicine, Hmc/Umng, Bogota, Colombia


Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Knowledge about the prevalence and data related to these comorbidities and risk factors in Latin America is limited.

Objectives To determine the prevalence of several comorbidities and risk factors for these comorbidities in patients with SpA in three Latin American countries, and to compare this prevalence with the rates in the general population investigating whether the prevalence is increased.

Methods Data of 390 consecutive patients with SpA enrolled in the international cross-sectional ASAS-COMOSPA study from Argentina, Colombia and Mexico were analysed. The prevalence rates (95% CI) of arterial hypertension (AHT), tuberculosis (TB), and malignancies (colon, melanoma, lung, lymphoma, prostate, cervix and breast) were estimated with continuity correction according to the method described by Wilson. The data from Colombian general population (adjusted per gender and age group) were obtained from the CARMELA study for AHT, from the National Health Surveillance Public System for TB and HBV and from the GLOBOCAN project for malignancies. The prevalence (95% IC) in SpA patients was compared with the prevalence rates in the Colombian general population by calculating age and gender-specific prevalences for AHT, TB and HBV, and calculating gender-specific prevalences for malignancies. SPSS Statistics 22 was used to perform the statistical analysis.

Results In total 64% were male, mean age of 45 (14.7) years and disease duration of 7.0 (8.1) years. The most common comorbidities were AHT (25.3%), hypercholesterolemia (21.8%), osteoporosis (9.4%) and gastrointestinal ulcer (7.8%). The prevalence of AHT was 25.3% (95% CI 21.2 to 29.4) and was significantly higher compared with the general population 13.4% (95% CI 11.5 to 15.2). The overall prevalence of TB was 3.33% (95% CI 1.8 to 5.7) and the prevalence of HBV infection was 1.03% (95% IC 0.3 to 2.7), both increased as compared with the general population (0.03% and 0.01% respectively). There was not an increased prevalence of cancers compared with general population.

Conclusions In patients with SpA, we found a higher prevalence of hypertension, tuberculosis and hepatitis B infections in three Latin America countries as compared with general population data. A systematic evaluation and screening of these comorbidities and risk factors may help to properly monitor and detect these conditions in SpA patients.

  1. Molto A, et al. Ann Rheum Dis 2015 Oct 21 pii: annrheumdis-2015–208174

  2. Gherghe AM, et al. RMD Open 2015 Sept 14;1(1):e000128

  3. Hernández-Hernández R, J Hypertens 2010, 28:24–34

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.